A clinician-led analysis of causation, confounding, and mental health risk interpretation
This cannabis psychosis risk review examines how the 2026 JAMA Internal Medicine paper interprets observational mental health data. The analysis explores confounding, reverse causation, exposure definition problems, and the difference between relative…
Endocannabinoid System Psychosis Risk: Clinical Research Guide
Clinical Takeaway Clinical Takeaway Patients presenting with cannabis-induced psychosis have measurable risk for developing schizophrenia spectrum or bipolar disorder, though distinguishing these primary psychiatric conditions from acute cannabis effects…
How Cannabidiol Modulates Glutamate in Psychosis Risk
A single dose of cannabidiol glutamate modulation psychosis effects was studied in people at clinical high risk for psychosis. CBD reduced abnormal hippocampal glutamate connections and irregular brain activity during memory tasks. This suggests…
Endocannabinoid System Clinical Research on Psychosis Risk
Patients with cannabis induced psychosis schizophrenia risk have a documented chance of developing schizophrenia spectrum or bipolar disorder. Clinical research highlights the importance of early identification and monitoring. Understanding this risk…
Understanding the Dangers of High-Potency Cannabis
High-potency cannabis risks are increasingly important as THC concentrations rise in legal markets. Clinical guidance on dosing and safety is essential to mitigate adverse effects. Understanding these risks helps clinicians counsel patients effectively.
Adolescent Cannabis Use & Mental Health Risk: Clinical Evidence
Adolescent cannabis psychotic disorder risk is supported by large population-based studies showing increased psychiatric diagnoses. Cannabis use during adolescence is linked to psychotic, bipolar, depressive, and anxiety disorders. This clinical evidence…
Exploring Endocannabinoid System and Adolescent Psychiatric Risk
Endocannabinoid system adolescent psychiatric risk is a critical area of study linked to cannabis use in teens. Research shows increased risk of psychotic, bipolar, depressive, and anxiety disorders. Understanding this risk helps guide clinical practice…
High-Potency Cannabis Linked to Dramatically Higher Risk of Psychotic Episodes
High-potency THC cannabis risk is strongly associated with increased chances of psychotic episodes. Research highlights that THC concentrations above 10-15% elevate this risk, particularly in adolescents and those with psychiatric history. Understanding…
Cannabis and Mental Health: Why ‘Cannabis’ and ‘d9-THC’ Are Not the Same
Cannabis mental health risk factors depend heavily on cannabinoid exposure, especially THC and CBD ratios. Understanding these factors is essential for assessing psychiatric outcomes. This article clarifies why cannabis and d9-THC are not interchangeable…
Cannabis and Mental Health: Why ‘It’s Complicated’ Is Actually the Most Accurate Answer
It is likely more appropriate to view cannabis use as a contributing factor to a condition with a multifactorial etiology (e.g., genetic predisposition, use of other drugs, familial and social factors), or the result of individuals having a shared…